We conducted an observational study to assess the use of total lymphocyte counts (TLC) alone and along with hemoglobin (Hb) as a predictor of CD4 count. A total of 103 antiretroviral therapy (ART)-naive HIV-1-infected patients were enrolled and divided in 2 groups (with CD4 count <200 cells/mm 3 and CD4 count 200 cells/mm 3 ). The TLC and Hb were performed by automatic full digital cell counter. CD4 count was determined by flow cytometry. Among the World Health Organization (WHO) clinical stages 2 and 3, in the cases with CD4 count <200 cells/mm 3 , 70.4% cases had TLC 1200 cells/mm 3 , whereas 63% cases had TLC 1200 cells/mm 3 þ Hb 12 g/dL. In the cases with CD4 count >200 cells/mm 3 , 2% cases had TLC 1200 cells/mm 3 , whereas adding Hb 12 g/dL with TLC 1200 cells/mm 3 , none of the cases would require initiation of ART. TLC þ Hb can be used to treat all HIV-infected patients with WHO stages 2 and 3 who have a TLC <1200 cells/mm 3 þ Hb 12 g/dL and to limit CD4 counts to patients who are symptomatic but have TLC þ Hb values other than TLC <1200 cells/mm 3 þ Hb 12 g/dL.
Introduction
Approximately, 33.2 million (30.6-36.1 million) people are living with HIV worldwide. Of these HIV-infected people, approximately 26.5 million (80%) people live in resourcelimited settings (RLS) of sub-Saharan Africa, as well as south and southeast Asia. 1 The survival benefits of antiretroviral therapy (ART) are well documented. 2 Depletion of CD4 count is one of the hallmarks of progression of HIV-1 infection. The determination of CD4 count has become a standard measure of immunodeficiency in adults infected with HIV in resource-rich areas where the burden of the pandemic is low. A major obstacle to the administration of ART in RLS, the majority of HIV-infected people live is the measurement of CD4 counts as it is expensive and often unavailable in less-developed areas. [2] [3] [4] [5] Although CD4 depletion count remains the most reliable marker for estimating the degree of immunosuppression in HIV-1-infected individuals, several authors have investigated the possible prognostic and predictive role offered by total lymphocyte count (TLC) as a surrogate of the CD4 count in RLS. Studies have shown good correlation between TLC and CD4 count, and TLC also offers the advantages of being less expensive and less complicated than the CD4 count. In addition, the equipment needed is already available in most RLS. [6] [7] [8] Anemia has been widely reported to predict a poorer prognosis for HIV-infected patients, both in terms of progression to AIDS and in terms of survival, independent of the CD4 count. Anemia in HIV infection is independently associated 9 with the progression of disease, mortality, and CD4 count < 200 cells/mm 3 . Similar to the decline seen in CD4 count, the accelerated decline in hemoglobin (Hb) preceding the development of AIDS defines a point at which highly active antiretroviral therapy (HAART) could be initiated. Algorithms including TLC and Hb improve the sensitivity of TLC as a surrogate marker of CD4 count. 7 As known worldwide, CD4 count is a standard measure of immunodeficiency in adults infected with HIV; however, there is a need to have another marker of immunodeficiency that is less resource demanding. We conducted an observational study to assess the use of TLC as a predictor of absolute CD4 count and to develop algorithms that improve the sensitivity of TLC as a predictor of absolute CD4 count to initiate the use of ART in a cohort of HIV-1-infected patients.
Materials and Methods
This study was conducted at the HIV Laboratory, Department of Microbiology and Haematology laboratory, Maulana Azad Medical College, New Delhi, India, which is a 1500-bed, tertiary care hospital catering to the health needs of the people of Delhi and adjoining states of northern India.
Participants
After the receipt of informed consent, 103 ART-naive HIV-1-infected patients at various stages of disease were studied. These patients underwent a clinical assessment for symptoms such as fever, weight loss, diarrhea, rash, and cough, and the clinical staging of study participants was done per World Health Organization (WHO) guidelines. Study participants were divided in 2 groups (with CD4 count of <200 cells/mm 3 [n ¼ 37] and CD4 count of 200 cells/mm 3 
Total Lymphocyte Counts, Hemoglobin, and CD4 Count
From each study participant, blood sample for TLC and CD4 count was collected at the same time in EDTA vacutainers. The TLC and Hb were performed by automatic full digital cell counter (MS9-3H; Melet Schloesing Laboratories, Osny, France). CD4 count was determined by flow cytometry using BD FACS Count analyzer (Becton Dickinson, Mountain View, CA), with controls and reagents provided by the manufacturers.
Statistical Analysis
Descriptive analysis of the baseline demographics of the population was performed. k Test was applied to find the agreement between clinical staging and TLC. Correlation coefficient between CD4 count and TLC was calculated using Pearson correlation test. Linear regression analysis was done to find the effect of variation of CD4 count on TLC. A P value <.05 was considered significant during all analyses.
Results
In total, 103 patients ranging from 18 to 48 years were included in the study. The demographic and baseline characteristics of the participants are summarized in Table 1 .
In patients with CD4 count <200 cells/mm 3 , 70.2% patients had a TLC 1200 cells/mm 3 (sensitivity, 89.6%; specificity, 85.1%; positive predictive value (PPV), 70.3; negative predictive value (NPV) 95.5; and P value ¼ .0001; Table 2 ). Among the cases with CD4 count 200 cells/mm 3 , 95.5% cases did not have TLC 1200 cells/mm 3 . k Test value for agreement of CD4 count with TLC is 0.69 (95% confidence interval [CI]: 0.53-0.77). A TLC 1200 cells/mm 3 has shown good agreement with CD4 count of <200 cells/mm 3 in WHO clinical stages 2 and 3.
Among the cases with CD4 count <200 cells/mm 3 , 62.2% cases had TLC 1200 cells/mm 3 plus Hb 12 g/dL (sensitivity, 92.0%; specificity, 82.1%; PPV, 62.2; NPV, 97.0; and P value ¼ .0001; Table 3 ). Among the cases with CD4 count 200 cells/ mm 3 , 97% cases did not have TLC <1200 cells/mm 3 þ Hb <12 g/dL. k Test value for agreement of CD4 count with TLC þ Hb was 0.64 (95% CI: 0.43-0.71). TLC 1200 cells/mm 3 þ Hb <12 g/dL has shown good agreement with CD4 count of <200 cells/mm 3 in WHO clinical stages 2 and 3. Adding Hb improved k agreement value for WHO stage 2 marginally.
The correlation coefficient r for CD4 counts and TLC was .524 (P ¼ .0001). The linear regression coefficient (b) was .52; that is, for each 1% increase in TLC, there was 0.52% increase in CD4 count. The model was capable of explaining only 27% (coefficient of determination, R 2 adjusted) of the variation. Figure 1 shows the relationship between CD4 count and TLC using the original scales of measurement (R 2 ¼ .268, P ¼ .0001).
Sensitivity, specificity, PPV, and NPV for different TLC cutoff values as compared to CD4 count of <200 cells/mm 3 are listed in Table 4 . A TLC of 1200 cells/mm 3 was found to have maximal sensitivity (70.3%), specificity (95.4%), PPV (89.7%), and NPV (84.9%) for predicting a CD4 count of <200 cells/mm 3 . 
Discussion
Per the WHO's general principle guidelines as to when to initiate ART, especially in WHO clinical stages 2 and 3 in RLS, setting, a wider availability of CD4 testing is an absolute requirement. However, the scarcity of this technology should not be a cause to defer treatment while the patient's condition deteriorates if there is an access to TLC and knowledge of clinical staging. Several studies revealed reasonably adequate sensitivity and specificity to consider TLC as a surrogate measure for CD4. [6] [7] [8] In our patients, with CD4 count <200 cells/mm 3 , 70.2% patients had a TLC 1200 cells/mm 3 (sensitivity, 89.6%; specificity, 85.1%; PPV, 70.3; and k-test value for agreement of CD4 count with TLC is .69), whereas in the studies 7,10 from the United States, TLC <1200 cells/mm 3 had the sensitivity range from 59% to 72%, specificity from 81% to 94%, and PPV from 47% to 85% for predicting CD4 counts <200 cells/mm 3 . This signifies that TLC may still be used in RLS, with the understanding of its low sensitivity and specificity which is also supported in a study from the United Kingdom, which indicated that despite minimally less reliability of TLC as a surrogate for CD4, TLC is an important tool in the absence of expensive equipment to measure CD4. 6 In our study participants, among the cases with CD4 counts <200 cells/mm 3 , 62.2% cases had TLC 1200 cells/mm 3 þ Hb 12 g/dL (sensitivity, 92.0%; specificity, 82.1%; PPV, 62.2; and k-test value for agreement of CD4 count with TLC þ Hb was .64). Addition of Hb <12 g/dL increased the sensitivity of TLC to 92% from 89% for predicting CD4 counts <200 cells/mm 3 but decreased the specificity to 82% from 85% compared to TLC alone which is in correlation with another study from the United States. 10 In our study, TLC 1200 cells/mm 3 was found to have maximal sensitivity (70.3%) and specificity (95.4%) for predicting a CD4 count of <200 cells/mm 3 (Table 4 ), whereas a study 5 from Africa found TLC 1780 cells/mm 3 to have maximal sensitivity (61%) and specificity (62%) for predicting a CD4 count of <200 cells/mm 3 . A study from the United States found TLC <1200 cells/mm 3 and Hb <12 g/dL to significantly predict CD4 counts <200 cells/mm 3 , which is in accordance with our study. 7 In a RLS, the difficulty regarding the initiation of ART arises basically in WHO clinical stages 2 and 3 because patients in stage 1 are asymptomatic and in stage 4, ART has to be initiated irrespective of immunological status. Among WHO clinical stages 2 and 3, in the cases with CD4 counts <200 cells/ mm 3 , that is patients who are eligible for ART, 70.4% cases had TLC 1200 cells/mm 3 , whereas 63% cases had TLC 1200 cells/mm 3 þ Hb 12 g/dL. However, in the cases with CD4 counts >200 cells/mm 3 , 2% cases had TLC 1200 cells/ mm 3 , which could lead to false initiation of ART, whereas adding Hb 12 g/dL with TLC 1200 cells/mm 3 , none of the cases would require initiation of ART. This indicates the significance of TLC þ Hb to treat all the patients in WHO stages 2 and 3 who have a TLC<1200 cells/mm 3 þ Hb12 g/dL and to limit the use of CD4 counts to patients who are symptomatic but have TLC þ Hb values other than TLC<1200 cells/mm 3 Figure 1 . Relationship between CD4 count and TLC. þ Hb12 g/dL. Using a TLC will reduce the number of patients requiring a CD4 count as suggested by another study from Africa. 8
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